DRUG-DRUG INTERACTIONS BETWEEN ARTEMETHER/LUMEFANTRINE AND LOPINAVIR/RITONAVIR IN HIV NEGATIVE HEALTHY VOLUNTEERS

DRUG-DRUG INTERACTIONS BETWEEN ARTEMETHER/LUMEFANTRINE AND LOPINAVIR/RITONAVIR IN HIV NEGATIVE HEALTHY VOLUNTEERS

Bibliographic Details
Main Authors:	German, P, Parikh, S, Lawrence, J, Havlir, D, Rosenthal, P, Dorsey, G, Lindegardh, N, Aweeka, F
Format:	Conference item
Published:	2008

Similar Items

Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
by: German, P, et al.
Published: (2009)

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
by: Byakika-Kibwika, P, et al.
Published: (2012)

Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine.
by: Ali, S, et al.
Published: (2010)

Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
by: Tarning Joel, et al.
Published: (2010-10-01)

Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
by: Mwesigwa, J, et al.
Published: (2010)

Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in falciparum-negative HIV-infected Malawian adults stabilized on antiretroviral therapy
by: Banda, CG, et al.
Published: (2018)

Artemether-lumefantrine and dihydroartemisinin-piperaquine exert inverse selective pressure on Plasmodium Falciparum drug sensitivity-associated haplotypes in Uganda
by: Taylor, A, et al.
Published: (2016)

Drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine
by: Walimbwa, S, et al.
Published: (2018)

Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria
by: Tchaparian, E, et al.
Published: (2016)

From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia.
by: Sipilanyambe, N, et al.
Published: (2008)

From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia
by: Sipilanyambe, N, et al.
Published: (2008)

CYP2B6*6 genotype specific differences in artemether‐lumefantrine disposition in healthy volunteers
by: Abdullahi, ST, et al.
Published: (2019)

Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz
by: German, P, et al.
Published: (2007)

Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz.
by: German, P, et al.
Published: (2007)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
by: Paola Magro, et al.
Published: (2021-03-01)

The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.
by: Mcgready, R, et al.
Published: (2006)

From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia
by: Snow Robert W, et al.
Published: (2008-01-01)

The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.
by: McGready, R, et al.
Published: (2009)

Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
by: Tarning, J, et al.
Published: (2009)

Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
by: Liusheng Huang, et al.
Published: (2017-01-01)

Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia.
by: Denis, M, et al.
Published: (2006)

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial
by: Kamya, MR, et al.
Published: (2007)

Potential clinically significant life-threatening drug–drug interactions of lopinavir and ritonavir used in the treatment of COVID-19
by: Mohitosh Biswas, et al.
Published: (2020-01-01)

Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets
by: Sileshi Belew, et al.
Published: (2020-04-01)

Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria
by: Sikiru Olatunji Usman, et al.
Published: (2020-11-01)

Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine
by: White, N, et al.
Published: (1999)

Recurrent oedema associated with the co-formulation of lopinavir and ritonavir Edema recorrente associado à co-formulação de lopinavir e ritonavir
by: Jorge Francisco C. Pinto, et al.
Published: (2004-08-01)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
by: Farinotti Robert, et al.
Published: (2010-05-01)

355 Lopinavir/ritonavir treatment in paediatric patients with covid-19
by: P Ip, et al.
Published: (2021-04-01)

Pharmaceutical quality of antimalarial drugs: quinine sulfate and Artemether/Lumefantrine tablets sold on Bukavu Market
by: Aladin Ombeni Mahano, et al.
Published: (2021-06-01)

Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
by: White, N, et al.
Published: (1999)

No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.
by: van Vugt, M, et al.
Published: (1999)

Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria.
by: van Vugt, M, et al.
Published: (2000)

A novel validated UPLC method for quantitation of lopinavir and ritonavir in bulk drug and pharmaceutical formulation with its impurities
by: Gnana Deepika Killi, et al.
Published: (2014-04-01)

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy
by: Linhu Ye, et al.
Published: (2021-11-01)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018-06-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
by: Kathleen M S E Reyskens, et al.
Published: (2013-01-01)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
by: Ashish Chandwani, et al.
Published: (2008-09-01)